Trials / Completed
CompletedNCT03092739
A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens
A Non-Interventional Multinational Study to Assess PD-L1 Expression in Cytological Versus Histological Non-Small Cell or Small Cell Lung Cancer Specimens
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 184 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this non-interventional, multinational study is to assess the feasibility of assessing PD-L1 protein expression on cytological samples as a surrogate for histological samples obtained from participants with any stage of non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | PD-L1 Immunocytochemistry (ICC) | PD-L1 expression in the cytological specimens will be assessed using different antibodies. |
| DIAGNOSTIC_TEST | PD-L1 Immunohistochemistry (IHC) | PD-L1 expression in the histological specimens will be assessed using different antibodies. |
Timeline
- Start date
- 2017-05-03
- Primary completion
- 2018-01-08
- Completion
- 2018-06-06
- First posted
- 2017-03-28
- Last updated
- 2019-07-23
Locations
8 sites across 6 countries: Czechia, Germany, Poland, Spain, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT03092739. Inclusion in this directory is not an endorsement.